Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CSTA

CSTA

Basics

Aliases:
This biomarker is also known as:
  • Stefin-A,
  • AREI,
  • cystatin AS,
  • STFA,
  • cystatin A (stefin A),
  • cystatin-A,
  • STF1,
  • Cystatin-AS,

View in BioMuta

Description…

CSTA, or cystatin-A, is a member of the cystatin superfamily, which includes proteins that contain multiple cystatin-like sequences. Some members of the cystatin superfamily are active cysteine protease inhibitors, of which there are three families: type 1 cystatins (stefins), type 2 cystatins, and kininogens. CSTA is a stefin that functions as a cysteine protease inhibitor, forming tight complexes with papain and the cathepsins B, H, and L. Stefins have been proposed as prognostic and diagnostic biomarkers for cancer.

Attributes

QA State: Curated
Type: Proteomic
Short Name:
HGNC Name: CSTA

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: One
QA State: Under Review

Overview

Studies have demonstrated an inverse relationship between increased cathepsin B expression and decreased CSTA in a variety of human tumors. Studies suggest that CSTA is one of the promising candidate biomarkers for lung cancer and deserves further investigation in lung tumorigenesis.

Performance Comment

CSTA belongs to a 9-member panel that provides a quantitative measure of the probability of having lung cancer that goes beyond the histological evaluation of preinvasive lesions. The identified members of the panel are TMSB4X (Thymosin beta-4), Ubiquitin, des-ubiquitin, ACBP, CSTA, Cytochrome C, and MIF.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.

Announcement